

Clinical and prognostic role of annexin A2 in multiple myeloma

Anja Seckinger,^{1,2} Tobias Meißner,¹ Jérôme Moreaux,^{3,4} Daniela Depeweg,⁵ Jens Hillengass,¹ Katja Hose,^{1,6} Thierry Rème,^{3,4} Angela Rösen-Wolff,⁷ Anna Jauch,⁸ Reinhard Schnettler,⁶ Volker Ewerbeck,⁵ Hartmut Goldschmidt,^{1,2} Bernard Klein,^{3,4} and Dirk Hose^{1,2}

¹Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany; ²Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany;

³Centre Hospitalier Universitaire Montpellier, Institute for Research in Biotherapy, Hôpital Saint-Eloi, Montpellier, France; ⁴Inserm U1040, Montpellier, France;

⁵Orthopädische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany; ⁶Klinik und Poliklinik für Unfallchirurgie, Universitätsklinikum Gießen und Marburg GmbH, Justus-Liebig-Universität Gießen, Gießen, Germany; ⁷Klinik und Poliklinik für Kinder und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; and ⁸Institut für Humangenetik, Universität Heidelberg, Heidelberg, Germany

Annexin A2 (ANXA2) promotes myeloma cell growth, reduces apoptosis in myeloma cell lines, and increases osteoclast formation. ANXA2 has been described in small cohorts of samples as expressed by myeloma cells and cells of the BM microenvironment. To investigate its clinical role, we assessed 1148 samples including independent cohorts of 332 and 701 CD138-purified myeloma cell samples from previously untreated patients together with clinical prognostic factors,

chromosomal aberrations, and gene expression–based high-risk scores, along with expression of ANXA2 in whole BM samples, stromal cells, osteoblasts, osteoclasts, and BM sera. ANXA2 is expressed in all normal and malignant plasma cell samples. Higher ANXA2 expression in myeloma cells is associated with significantly inferior event-free and overall survival independently of conventional prognostic factors and is associated with gene expression–determined

high risk and high proliferation. Within the BM, all cell populations, including osteoblasts, osteoclasts, and stromal cells, express ANXA2. ANXA2 expression is increased significantly in myelomatous versus normal BM serum. ANXA2 exemplifies an interesting class of targetable bone-remodeling factors expressed by normal and malignant plasma cells and the BM microenvironment that have a significant impact on survival of myeloma patients. (*Blood*. 2012;120(5):1087-1094)

Introduction

Multiple myeloma is a rarely curable, malignant disease of clonal plasma cells that accumulate in the BM, causing clinical signs and symptoms related to the displacement of normal hematopoiesis, formation of osteolytic bone lesions, and the production of monoclonal protein.^{1,2} Multiple myeloma cells harbor a high median number of chromosomal aberrations³⁻⁵ and multiple changes in gene expression compared with normal BM plasma cells.⁶⁻¹¹ The corresponding myelomatous BM is altered significantly due to factors that are expressed aberrantly by myeloma cells, those that are already expressed by normal plasma cells but present in higher abundance,^{6,8} and those expressed by a variety of cells of the (changing) BM microenvironment.^{9,12-14}

One of these factors recently described is annexin A2 (ANXA2), a calcium-dependent, phospholipid-binding member of the annexin family. ANXA2 is interesting in myeloma biology because it has long been known to be up-regulated in small cohorts of myeloma cell samples compared with normal plasma cells¹⁵ and in human myeloma cell lines.¹⁶ Its receptor, AX2R,¹⁷ has been shown recently to be expressed by cell lines and primary myeloma cells, supporting myeloma cell growth and adhesion to stromal cells.¹⁸ ANXA2 stimulates angiogenesis,^{19,20} osteoblastic mineralization,²¹ and proliferation and differentiation of osteoclast precursors.²²⁻²⁴ Despite its seeming biologic relevance in myeloma, nothing is known about the clinical and prognostic significance of ANXA2.

Therefore, in the present study, we investigated the clinical role of ANXA2 in multiple myeloma by assessing its expression and

that of its receptor in 1148 samples, including independent cohorts of 332 and 701 CD138-purified myeloma cells from previously untreated patients, together with clinical prognostic factors, chromosomal aberrations, and gene expression–based high-risk scores.²⁵⁻²⁷ We also assessed the expression of ANXA2 in 161 corresponding whole BM samples, 15 mesenchymal stromal cells, 8 osteoblasts, 7 osteoclasts, and 25 BM sera samples.

We found ANXA2 to be expressed in all normal and malignant plasma cell samples. Higher ANXA2 expression in primary myeloma cells was associated with significantly inferior event-free (EFS) and overall survival (OS) independently of conventional prognostic factors and was associated with gene expression–determined high risk (ie, by the University of Arkansas for Medical Sciences score²⁶ and the Intergroupe Francophone du Myélome score²⁵) and proliferation.²⁷ Within the BM, all cell populations, including osteoblasts, osteoclasts, and mesenchymal stromal cells, express ANXA2. On the protein level, ANXA2 expression is increased significantly in myelomatous compared with normal BM serum. As in primary myeloma cells, high ANXA2 expression in the whole BM samples is associated with significantly inferior EFS and OS.

Therefore ANXA2 exemplifies an interesting class of targetable bone-remodeling impacting factors expressed by normal and malignant plasma cells and cells of the BM microenvironment, which has a significant impact on survival in multiple myeloma patients.

Submitted March 8, 2012; accepted June 6, 2012. Prepublished online as *Blood* First Edition paper, June 15, 2012; DOI 10.1182/blood-2012-03-415588.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

The online version of this article contains a data supplement.

© 2012 by The American Society of Hematology

Methods

Patients and healthy donors

Patients presenting with previously untreated multiple myeloma ($n = 332$) or monoclonal gammopathy of unknown significance ($n = 22$) at the University Hospitals of Heidelberg and Montpellier and 10 healthy donors were included in the study. The study was approved by the Heidelberg ethics committee (#229/2003 and S-152/2010) after written informed consent in accordance with the Declaration of Helsinki. Patients were diagnosed, staged and response to treatment assessed according to standard criteria.²⁸⁻³⁰ For clinical parameters, see supplemental Table 1 (available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). A total of 247 patients underwent frontline high-dose chemotherapy with 200 mg/m² of melphalan and autologous stem cell transplantation. Survival data were validated by an independent cohort of 701 patients treated within the total therapy 2 or 3 protocol, respectively.^{31,32}

Samples

For an overview of samples used, see supplemental Table 2. Normal BM plasma cells and myeloma cells were purified as described previously.⁶⁻⁸ Aliquots of unpurified whole BM of myeloma patients ($n = 154$) and healthy donors ($n = 7$) were obtained after NH₄ lysis.¹² Alternate aliquots were subjected to FACS sorting (FACS Aria; BD Biosciences) in CD3⁺, CD14⁺, CD15⁺, and CD34⁺ cells. Peripheral CD27⁺ memory B cells ($n = 11$) were FACS sorted as described previously.³³ The human myeloma cell lines U266, RPMI-8226, LP-1, OPM-2, SK-MM-2, AMO-1, JIN-3, NCI-H929, KMS-12-BM, KMS-11, KMS-12-PE, KMS-18, MM1.S, JIM3, KARPAS-620, L363, and ANBL6 were purchased from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) and ATCC. The XG lines were generated at Inserm U1040 (Montpellier, France).³⁴ Polyclonal plasmablastic cells ($n = 10$), osteoclasts ($n = 7$), and mesenchymal stromal cells ($n = 15$) were generated as described previously.^{6,35,36} Mesenchymal stromal cells ($n = 8$) were in vitro differentiated into osteoblasts according to published protocols.³⁷

Interphase FISH

For an overview of the FISH probes used (Kreatech Diagnostics), see supplemental Table 2. Analyses were performed on CD138-purified plasma cells as described previously.³ The score of Wuillemet et al was used to assess ploidy.³⁸

Gene-expression profiling

Gene-expression profiling was performed as described previously (Heidelberg-Montpellier [HM] group)^{6-8,27} using U133 Version 2.0 plus arrays according to the manufacturer's instructions (Affymetrix). Expression data were deposited in ArrayExpress under the accession numbers E-MTAB-317 and E-TABM-1138 and in the Gene Expression Omnibus as GSE24080 (the latter 2 for the Little Rock [LR] group).

Validation of gene-expression profiling using real-time PCR

Expression of *ANXA2* (Hs00733393_m1; Applied Biosystems) was assessed by real-time PCR using the StepOnePlus Real-Time PCR System (Applied Biosystems) for $n = 10$ myeloma cell lines and $n = 10$ primary myeloma cell samples.

Western blotting

Cell lysates were prepared as described previously.⁶ In brief, after pelleting, supernatants were mixed with loading buffer (Carl Roth), heated for 5 minutes at 95°C, and separated on 10% NuPAGE Bis-tris gels (Invitrogen). Immunodetection was performed using the Western Breeze Kit (Invitrogen). Membranes were incubated with Abs against *ANXA2* (clone: 5), and β -actin (clone Ab5; both BD Biosciences) as a loading control.

Flow cytometric analysis of ANXA2

Intracellular *ANXA2* expression in 10 myeloma cell lines was assessed using a fixation and permeabilization kit according to the manufacturer's instructions (NatuTec). Cells were stained with the corresponding primary Ab (see preceding paragraph) and secondary Ab (Vector Laboratories). Analyses were performed by FACS Aria and FlowJo Version 7.5.5 software (TreeStar) for obtaining overlays.

ELISA

ANXA2 levels were measured in culture supernatants of myeloma cell lines ($n = 10$) and primary myeloma cells ($n = 8$) and in the BM sera of healthy donors ($n = 10$) and myeloma patients ($n = 15$) using a commercially available ELISA kit (USCN Life Science). For the supernatants, 1×10^6 cells per milliliter were cultured for 24 hours in serum-free RPMI 1640 medium (Invitrogen).

Assessment of myeloma bone disease

Bone disease as assessed by conventional X-ray and whole-body CT scan in routine diagnostics was graded as 0 (normal bone structure), 1 (osteopenia/osteoporosis), 2 (1-3 osteolyses), or 3 (major structural damage, > 3 osteolyses).

Statistical analysis

Gene-expression analyses were performed on GC-RMA³⁹ preprocessed datasets of the B-cell lineage and the whole BM samples. For direct comparison of the expression values of plasma cells and BM microenvironment (subpopulations), all samples were preprocessed together. Because of 2 different IVT labeling kits used, batch correction was performed using ComBat.⁴⁰ To assess the presence or absence of gene expression, the "Presence-Absence calls with Negative Probesets" algorithm⁴¹ was used. Differences in clinical parameters and cytogenetics and differences between defined groups were investigated by exact Wilcoxon rank-sum test. Correlation was assessed using the Pearson correlation coefficient or the Kendall τ coefficient (for categorical variables). The relationship between categorical variables was assessed using the Fisher exact test. Differential gene expression was assessed using empirical Bayes statistics in linear models for microarray data.⁴² *P* values were adjusted for multiple testing controlling the false discovery rate as defined by Benjamini and Hochberg.⁴³ All computations were performed using R Version 2.14.1 (<http://www.r-project.org/>) and Bioconductor Version 2.9 software.⁴⁴ EFS and OS were investigated using the Cox proportional hazard model.⁷ First, *ANXA2* expression was taken as a continuous variable. Second, *ANXA2* expression was tested in a Cox model together with either serum- β 2-microglobulin (B2M) or the International Staging System (ISS). Next, 2 groups of patients with high (*ANXA2*^{high}) and low (*ANXA2*^{low}) *ANXA2* expression were delineated using maximally selected rank statistics as implemented in the maxstat R package (<http://cran.r-project.org/web/packages/maxstat/index.html>). For EFS and OS, cutoffs were calculated as the mean cutoff from EFS and OS, respectively. Gene expression-based assessment of risk and proliferation and classifications of myeloma were performed as described previously.²⁷ Findings were validated using the same strategy on the independent group of 701 patients from the LR group. An effect was considered to be statistically significant if the *P* value of its corresponding statistical test was not higher than 5%.

Results

Expression of ANXA2 and AX2R

ANXA2 (located at 15q21-q22) is expressed by all normal and malignant plasma cells and precursors of the B-cell lineage (Figure 1A). Whereas there was no significant difference in median *ANXA2* expression between normal and malignant plasma cells, expression was significantly higher compared with memory B cells




Figure 1. Expression of ANXA2 and validation of gene expression by flow cytometry and Western blotting. (A) Expression of ANXA2 and its receptor, AX2R, in memory B cells (MBCs), polyclonal plasmablastic cells (PPCs), normal plasma cells (BMPCs), myeloma cells (MMCs) and human myeloma cell lines (HMCLs). (B) To validate gene-expression data, the expression of ANXA2 was determined by flow cytometry. Light gray line indicates control without primary Ab; black line, measurement with the corresponding primary and secondary Abs. All cell lines show a consistent expression of ANXA2 by gene-expression profiling, real-time PCR, flow cytometry, and Western blotting (C). For Western blotting, β-actin was used as loading control.

($P < .001$), but significantly lower compared with proliferating cells, plasmablasts ($P = .003$), and human myeloma cell lines ($P < .001$). There was no difference between myeloma cells from early-stage (monoclonal gammopathy of unknown significance and myeloma Durie-Salmon stage I) and advanced-stage (myeloma Durie-Salmon stage II and III) patients.

The ANXA2 receptor AX2R (located at 5p12) was expressed in all normal and malignant plasma cell samples without significant change throughout plasma cell differentiation or between different stages of plasma cell dyscrasias.

Expression of ANXA2 in myeloma cells was validated by real-time PCR. It was expressed in 10 of 10 myeloma cell lines and

10 of 10 primary myeloma cell samples. Results could be confirmed on the protein level using flow cytometry (Figure 1B) and Western blotting (Figure 1C).

In the whole BM, ANXA2 and AX2R were also expressed at a comparable level in healthy and myelomatous (whole) BM samples (Figure 2). Considering cells of the BM microenvironment, ANXA2 expression was significantly higher in osteoblasts and osteoclasts and their corresponding precursors, mesenchymal stromal cells and CD14⁺ monocytes/macrophages, respectively, compared with myeloma cells ($P < .001$, each; Figure 2). Expression of ANXA2 was significantly higher in differentiated osteoclasts compared with CD14⁺ precursor cells ($P < .001$) and slightly (1.4-fold) but




Figure 2. Expression of ANXA2 in the whole BM and cells within. Expression of ANXA2 is shown in the whole BM of myeloma patients (WBM-MM) and normal donors (WBM-ND) as well as osteoclasts (OCs), osteoblasts (OBs), and their precursors, mesenchymal stromal cells (MSCs) and CD14⁺ monocytes/macrophages (CD14), respectively, compared with normal (BMPCs) and malignant (MMCs) plasma cells.

significantly lower in differentiated osteoblasts compared with undifferentiated mesenchymal stromal cells ($P < .001$).

Secretion of ANXA2

By ELISA, secretion of ANXA2 could be found in supernatants of primary myeloma cells (0.42 ± 0.55 ng/mL) and in myeloma cell lines (0.14 ± 0.08 ng/mL; the minimum detectable dose given by the manufacturer is typically less than 0.084 ng/mL). The mean ANXA2 secretion in BM sera from myeloma patients (6.67 ± 6.47 ng/mL) was significantly higher compared with normal donors (1.4 ± 1.43 ng/mL; $P = .009$).

Association of ANXA2 expression with clinical parameters

We did not find any correlation for clinical parameters (including Durie-Salmon stage, B2M, serum albumin, or ISS) with ANXA2 expression. Using the log-rank–based threshold, we likewise found no difference of the clinical parameters in ANXA2^{high}- compared with ANXA2^{low}-expressing patients.

Association of ANXA2 expression with genetically defined (sub)entities of multiple myeloma

We found a slightly but significantly higher expression in patient myeloma cells harboring a t(4;14) translocation ($P < .001$), and a significantly lower expression in those harboring a t(11;14) translocation ($P = .02$). No difference was found for myeloma cell samples of hyperdiploid patients or those harboring a gain of 11q13, 15q22 (the ANXA2-locus), or 5p15, the AX2R locus. Of the aberrations associated with disease progression, deletion of 13q14 ($P = .008$) and gain of 1q21 ($P < .001$), but not deletion of 17p13, showed increased ANXA2 expression. The same held true for losses of 4p16 ($P < .001$) and 14q32 ($P = .006$). If delineated in terms of samples with high and low ANXA2 expression, in the ANXA2^{high} group, significantly more patients harbored a t(4;14) ($P = .007$) or gain of 1q21 ($P < .001$) translocation, as well as a loss of 4p16 ($P = .005$) or 14q32 ($P = .001$).

We also investigated the association of ANXA2 expression, cyclin D expression, and gene expression–based classifications of multiple myeloma.^{10,11,27} Lower CCND1 expression ($P = .01$) but higher CCND2 expression ($P = .04$), respectively, was significantly associated with a higher ANXA2 expression. This is in agreement with our finding of a significantly lower expression in patients harboring a t(11;14) mutation. However, we did not find any significant association of ANXA2 expression with the molecular classifications.

Association of ANXA2 expression with gene expression–based high-risk scores and proliferation

Although there was no correlation with gene expression–based high-risk scores,²⁵⁻²⁷ all of the respective high-risk groups showed a slightly but significantly higher ANXA2 expression in primary myeloma cells (1.4-fold; gene expression-based proliferation index, $P < .001$; University of Arkansas for Medical Sciences score, $P < .001$; Intergroupe Francophone du Myélome score, $P < .001$). The same was true for the gene expression-based proliferation index on the data of the LR group (2.0-fold; $P < .001$).

Association of ANXA2 expression with bone disease

We did not find a direct association of ANXA2 expression in primary myeloma cells with the extent of myeloma-induced bone disease, and only a slight tendency in whole BM ($P = .2$). Likewise, ANXA2 expression was not correlated with Dickkopf-1

(DKK-1) expression, the most prominent myeloma bone disease–associated gene,⁴⁵ nor did the ANXA2^{high}-expressing group show elevated Dickkopf-1 expression values.

Prognostic value of ANXA2 and AX2R

Expression in primary myeloma cells. As a single continuous variable, ANXA2 expression in primary myeloma cells was significantly predictive for EFS and OS in both cohorts tested (all $P < .001$). Tested with B2M (continuous), both factors were independent for OS in the HM data (ANXA2, $P < .001$; B2M, $P < .001$) and the LR data (ANXA2, $P < .001$; B2M, $P < .001$). The same held true if ANXA2 expression was tested with ISS in the HM data (ANXA2, $P < .001$; ISS, $P = .002$) and the LR data (ANXA2, $P = .01$; ISS, $P < .001$). For EFS, ANXA2 remained an independent prognostic factor if tested with B2M (ANXA2, $P < .001$; B2M, $P = .001$) or ISS (ANXA2, $P < .001$; ISS, $P = .01$) in our data and in the LR data (ANXA2, $P < .001$; B2M, $P < .001$), but not if tested with ISS (ANXA2; $P = .2$; ISS $P < .001$).

In agreement with this, patients with ANXA2^{high}-expressing versus ANXA2^{low}-expressing myeloma cells showed a significantly inferior OS ($n = 247$; $P < .001$, hazard ratio [HR] = 2.3; 95% confidence interval [95% CI], 1.4-3.6; Figure 3) and EFS ($n = 247$; $P = .004$; HR = 1.6; 95% CI, 1.2-2.3). Similar observations were found with the patient cohort from the LR group ($n = 701$; OS, $P < .001$; HR = 2.1; 95% CI, 1.6-2.8 and EFS, $P < .001$; HR = 1.6; 95% CI, 1.2-2.1; Figure 3). The expression of the ANXA2 receptor AX2R had no prognostic value.

Expression in whole BM. The same prognostic effect for the expression of ANXA2 could be found within the whole BM. Patients with a high ANXA2 expression had a significantly inferior OS ($n = 154$; $P = .001$) and EFS ($n = 154$; $P = .05$) compared with patients with a low ANXA2 expression (Figure 4). Likewise, there was no correlation with the plasma cell infiltration.

Discussion

Biologic role of ANXA2 and AX2R expression

In the present study, we have shown that ANXA2 and its receptor, AX2R, are expressed in all normal and malignant plasma cell samples and their precursors in a large cohort of myeloma patients (Figure 1), validating earlier data.^{16,18} ANXA2 expression was associated with different disease entities, that is, translocation t(4;14) and t(11;14), disease progression (gain of 1q21), proliferation (which is in turn associated with 1q21-gain²⁷), gene expression–based risk scores, and survival (Figure 3). In addition to normal and malignant plasma cells, ANXA2 and AX2R are expressed by a variety of cell types (Figure 2). In whole BM samples, ANXA2 was likewise significantly associated with patient survival (see next paragraph). These findings are even more remarkable because the variation in expression height within the respective populations was relatively small (Figure 1 and discussion in next paragraph). On the protein level, ANXA2 was present (secreted) in normal BM serum, whereas it was significantly increased in myelomatous BM.

Our results mirror the biologic role of ANXA2 that triggered our study: ANXA2 has been shown to stimulate myeloma cell growth and proliferation and to inhibit apoptosis.^{16,18} At least some of these effects are exerted via the MAPK-dependent activation of the ERK1/2 and AKT pathway,^{18,24} both of which are present in myeloma cells. ANXA2 has also been shown to increase osteoclast




Figure 3. Effect of ANXA2 expression on EFS and OS. OS (A) and EFS (B) for our patients (HM group; n = 247) and the LR group (n = 701). All patients were treated with high-dose chemotherapy and autologous stem cell transplantation. Two groups of patients with low (ANXA2^{low}, black curve) and high (ANXA2^{high}, gray curve) ANXA2 expression could be delineated. The OS was significantly superior for low ANXA2 expression (HM group, $P < .001$ and LR group, $P < .001$). The same held true for EFS in the HM group ($P = .004$) and the LR group ($P < .001$).

formation by stimulating proliferation and differentiation of osteoclast precursors.^{16,18,22-24} Based on these biologic activities, the presence of secreted ANXA2 in normal BM sera indicates a role in physiologic bone turnover and, eventually, for survival of normal BM plasma cells. Therefore, its pathophysiologic role could mirror its physiologic one. ANXA2 expression in normal plasma cells could therefore mediate the interaction with the microenvironment (eg, during the “niching” of plasma cells in interaction with osteoblasts, their precursors, and osteoclasts as a local “small scale variant” of myeloma induced bone disease). With the increase in ANXA2 level in myelomatous BM, these interactions gain importance in maintaining myeloma cell survival and increased bone turnover, presumably being (at least in part) responsible for myeloma-induced bone disease.

An interesting question can be raised: why are there high levels of ANXA2 present in BM serum samples from myeloma patients compared with normal individuals, but no difference can be found regarding ANXA2 expression in terms of gene expression in whole BM samples and why is there no association with plasma cell

infiltration? The answer lies in what is measured by gene-expression profiling or PCR versus measuring ANXA2-levels in BM sera directly: gene expression is the integral median expression of the populations within the sample because a fixed range of material is used (typically 100 ng of RNA) independently of the total number of cells within the sample. Therefore, this value does not change related to an absolute increase in cellularity and in turn does not mirror the total production of a factor increasingly produced by a higher number of cells. Therefore, an increase in plasma cell infiltration does not lead to a change in the integral median of ANXA2 expression over the mixture of populations in the BM, because the expression level of ANXA2 of myeloma cells is comparable with the expression level of the whole BM (Figure 2). This is in contrast to BMP6 being exclusively expressed by normal and malignant plasma cells only, which correlates significantly with plasma cell infiltration and expression within the whole BM.⁸ Because plasma cell accumulation leads to an absolute increase in cellularity, the number of ANXA2-producing cells augments especially the




Figure 4. Effect of ANXA2 expression within the BM on EFS and OS. Shown are OS (A) and EFS (B; $n = 154$). Two groups of patients with low (ANXA2^{low}, black curve) and high (ANXA2^{high}, gray curve) ANXA2 expression. OS was significantly superior for low ANXA2 expression ($P = .001$); the same held true for EFS ($P = .05$).

number of ANXA2-secreting myeloma cells, because this population has the highest relative and absolute increase in number. Therefore, the total amount of ANXA2 secretion in the whole BM increases because the number of secreting cells is increasing, not the secretion of an individual cell. This situation is comparable with the expression of proangiogenic factors (eg, VEGFA) by normal plasma cells at a similar level to myeloma cells, leading to an absolute increase in the amount of secreted factors by an increase in plasma cell infiltration, and in turn, induction of angiogenesis.⁶

ANXA2 expression and bone disease

On first view, the lack of a clear association between osteolytic bone disease as detected by conventional and whole-body CT imaging is disappointing and difficult to understand. With a second look, it is not. First, ANXA2-related bone disease is likely driven by the absolute increase in secreted ANXA2 within the BM, not visible in gene expression (as discussed above), making it difficult to discern an association. Second, despite being associated with biologic entities and prognosis, the expression of ANXA2 in myeloma cells does not show a significant up-/down-regulation compared with normal plasma cells (eg, in contrast to DKK1).⁴⁵ Given our present data and its biologic function, ANXA2 could be involved in normal bone turnover and niching of BM plasma cells. A “highjacking” of these physiologic mechanisms by myeloma cells might accordingly be present in the majority of myeloma patients, giving ANXA2 a special place alongside other aberrantly expressed bone metabolism impacting factors such as DKK1 or IL-6.

ANXA2 expression and survival

In the present study, we show for the first time ANXA2 expression in primary myeloma cells as an adverse prognostic factor in 2 independent cohorts of patients undergoing high-dose chemotherapy and autologous stem-cell transplantation (Figure 3). Compared with other expression-based prognostic factors, such as IGF1 in primary myeloma cells⁴⁶ or heparanase in the BM microenvironment,¹² it must be emphasized that the median of both ANXA2^{high}- and ANXA2^{low}-expressing myeloma cells is in the range of ANXA2 expression in normal plasma cells. In addition, ANXA2 expression in the whole BM is a prognostic factor (Figure 4).

What is the basis for the impact of ANXA2 expression on survival? First, in multivariate analysis, the prognostic impact of ANXA2 expression is independent of conventional prognostic factors, basically mirroring tumor load (eg, B2M and ISS stage). Second, it is associated with molecular entities related to high risk such as 1q21 gain and del13q14 (despite not being significant as a single aberration) and t(4;14) (despite its reduced significance in patients treated with bortezomib).³ ANXA2 is also associated with prognosis-associated gene expression-based high-risk scores^{25,26} and also with myeloma cell proliferation, one of the strongest independent risk factors in myeloma.²⁷ This makes 2 interpretations possible: (1) ANXA2 expression by its biologic functions drives part of the adverse prognosis in genetically defined high-risk myeloma, or (2) ANXA2 expression surrogates another factor changing in the same way without any functional relationship between the two. Proliferation could be such a factor: ANXA2 is up-regulated in normally proliferating plasmablastic cells and human myeloma cell lines (Figure 1) and is associated with gene expression-based assessment of proliferation in malignant plasma cells. Part of the adverse biologic impact of genetically defined high-risk myeloma is related to proliferation such as gain of 1q21, deletion of 13q14, and gene expression-based high-risk scores.²⁷ Given the biologic impact on bone turnover and myeloma cell survival, there is at least reason to lean to the first possibility.

In other cancer entities, ANXA2 expression seems to have either beneficial or detrimental effects on patient survival. An increased expression of ANXA2 has been reported as a poor prognostic factor for solid tumors such as pancreatic⁴⁷ and breast cancer,⁴⁸ being associated with progression, invasion, and metastatic spread of tumor cells. Conversely, ANXA2 expression is down-regulated in prostate cancer,⁴⁹ promoting (osteoblastic) bone

metastasis.⁵⁰ Therefore, ANXA2 expression seems to be a general prognostic factor in cancer, but might be associated or surrogate a different pathogenic mechanism in different entities.

ANXA2 as therapeutic target

Given the wide distribution of ANXA2 expression over different cell types (Figure 2) and the concomitant possibility of off-target effects, a therapeutic strategy may lie not in targeting the ANXA2-expressing cell per se, but in directly decreasing the ANXA2-level in myelomatous BM to at least normal levels, for example, by the use of mAbs or “decoy” receptors against ANXA2. Counteracting the biologic functions of ANXA2, this decrease could act in 3 ways: (1) by reducing bone turnover and thus myeloma-induced bone disease as one of the main clinical challenges in myeloma treatment; (2) by hindering the concomitant liberation of myeloma growth and survival factors as IGF1; and (3) by preventing the direct stimulation of myeloma cell proliferation and survival. Taking into account the adverse prognosis of patients with ANXA2^{high}-expressing myeloma cells, it might even be that these are more dependent on high ANXA2 levels, and therefore anti-ANXA2 treatment is to a certain degree risk adapted.

ANXA2 as one of a novel class of prognostic factors involved in myeloma pathogenesis

We conclude that ANXA2 is a member of a novel class of prognostic factors involved in myeloma pathogenesis with the following characteristics: high expression in normal and malignant plasma cells (no differential expression); comparable expression in several other cell types; clear association with molecular entities and risk (direct and indirect), with adverse prognosis for higher expression (even if “high” is still within the normal range); and an increase in BM serum levels not visible in expression profiling of the BM microenvironment.

In conclusion, ANXA2 exemplifies an interesting class of targetable bone-remodeling impacting factors expressed by normal

and malignant plasma cells and cells of the BM microenvironment with significant impact on survival in multiple myeloma patients.

Acknowledgments

The authors thank Véronique Pantescio, Gabriele Hoock, Maria Dörner, and Katrin Heimlich for technical assistance.

This work was supported in part by grants from the Deutsche Forschungsgemeinschaft (SFB/TRR79; Bonn, Germany), the Dietmar Hopp Foundation (St Leon-Rot, Germany), the University of Heidelberg (Heidelberg, Germany), the Orthopädische Klinik (Heidelberg, Germany), and the Ligue Nationale Contre Le Cancer (Paris, France). Plasma cell purification was supported in part by Novartis Pharma (Nuremberg, Germany).

Authorship

Contribution: A.S. and D.H. designed the research, performed the experiments, analyzed the data, and wrote the manuscript; T.M. and T.R. performed the statistical analysis; J.M. performed the microarray experiments; D.D. analyzed the X-rays and whole-body CT scans; J.H. collected BM samples and clinical data; K.H. and R.S. participated in the conceptual work of the SFB/TRR79; A.R.-W. participated in data analysis; A.J. performed the interphase-FISH experiments; V.E. reviewed the manuscript; H.G. collected BM samples and clinical data and reviewed the manuscript; and B.K. analyzed the data and reviewed the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Dr Dirk Hose, Medizinische Klinik V, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany; e-mail: dirk.hose@med.uni-heidelberg.de.

References

- Kyle RA, Rajkumar SV. Multiple myeloma. *N Engl J Med*. 2004;351(18):1860-1873.
- Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem auto-transplant trial for multiple myeloma. *Br J Haematol*. 2006;135(2):158-164.
- Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. *Blood*. 2012;119(4):940-948.
- Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. *Cancer Res*. 2004;64(4):1546-1558.
- Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. *Blood*. 2007;109(8):3489-3495.
- Hose D, Moreaux J, Meissner T, et al. Induction of angiogenesis by normal and malignant plasma cells. *Blood*. 2009;114(1):128-143.
- Hose D, Rème T, Meissner T, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. *Blood*. 2009;113(18):4331-4340.
- Seckinger A, Meissner T, Moreaux J, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. *Oncogene*. 2009;28(44):3866-3879.
- Caers J, Hose D, Kuipers I, et al. Thymosin beta4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. *Haematologica*. 2010;95(1):163-167.
- Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. *Blood*. 2006;108(6):2020-2028.
- Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. *J Clin Oncol*. 2005;23(26):6333-6338.
- Mahtouk K, Hose D, Raynaud P, et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. *Blood*. 2007;109(11):4914-4923.
- Mahtouk K, Hose D, Rème T, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. *Oncogene*. 2005;24(21):3512-3524.
- Klein B, Seckinger A, Moehler T, Hose D. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. *Recent Results Cancer Res*. 2011;183:39-86.
- Munshi NC, Hideshima T, Carrasco D, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. *Blood*. 2004;103(5):1799-1806.
- Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. *Int J Hematol*. 2009;90(2):177-185.
- Lu G, Maeda H, Reddy SV, et al. Cloning and characterization of the annexin II receptor on human marrow stromal cells. *J Biol Chem*. 2006;281(41):30542-30550.
- D'Souza S, Kurihara N, Shiozawa Y, et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. *Blood*. 2012;119(8):1888-1896.
- Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. *Curr Pharm Des*. 2007;13(35):3568-3575.
- Ling Q, Jacovina AT, Deora A, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. *J Clin Invest*. 2004;113(1):38-48.
- Gillette JM, Nielsen-Preiss SM. The role of annexin 2 in osteoblastic mineralization. *J Cell Sci*. 2004;117(3):441-449.
- Mena C, Devlin RD, Reddy SV, Gazitt Y, Choi SJ, Roodman GD. Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures. *J Clin Invest*. 1999;103(11):1605-1613.
- Takahashi S, Reddy SV, Chirgwin JM, et al. Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast

- formation and bone resorption. *J Biol Chem*. 1994;269(46):28696-28701.
24. Li F, Chung H, Reddy SV, et al. Annexin II stimulates RANKL expression through MAPK. *J Bone Miner Res*. 2005;20(7):1161-1167.
 25. Decaux O, Lodé L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. *J Clin Oncol*. 2008;26(29):4798-4805.
 26. Shaughnessy JD, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. *Blood*. 2007;109(6):2276-2284.
 27. Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. *Haematologica*. 2011;96:87-95.
 28. Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. *J Clin Oncol*. 2005;23(15):3412-3420.
 29. Durie BG. Staging and kinetics of multiple myeloma. *Semin Oncol*. 1986;13(3):300-309.
 30. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. *Br J Haematol*. 1998;102(5):1115-1123.
 31. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. *Blood*. 2006;107(7):2633-2638.
 32. van Rhee F, Szymonifka J, Anaissie E, et al. Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy. *Blood*. 2010;116:1220-1227.
 33. Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. *Blood*. 2005;106(3):1021-1030.
 34. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. *Blood*. 1994;83(12):3654-3663.
 35. Corre J, Mahtouk K, Attal M, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. *Leukemia*. 2007;21(5):1079-1088.
 36. Fuhler GM, Baanstra M, Chesik D, et al. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. *Exp Cell Res*. 2010;316(11):1816-1828.
 37. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Exp Hematol*. 2005;33(11):1402-1416.
 38. Wulleme S, Robillard N, Lodé L, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. *Leukemia*. 2005;19(2):275-278.
 39. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. *J Am Stat Assoc*. 2004;99:909-917.
 40. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics*. 2007;8(1):118-127.
 41. Warren P, Taylor D, Martini PGV, Jackson J, Bienkowska J. PANP—a new method of gene detection on oligonucleotide expression arrays. *2007 BIBE 2007 Proceedings of the 7th IEEE International Conference on Bioinformatics and Bioengineering*. 2007;108-115.
 42. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol*. 2004;3:Article3.
 43. Benjamini Y, Hochberg Y. Controlling the false discovery: a practical and powerful approach to multiple testing. *J R Stat Soc Series B*. 1995;57:289-300.
 44. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol*. 2004;5(10):R80.
 45. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. *N Engl J Med*. 2003;349(26):2483-2494.
 46. Sprynski AC, Hose D, Caillot L, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. *Blood*. 2009;113(19):4614-4626.
 47. Esposito I, Penzel R, Chaib-Harriche M, et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. *J Pathol*. 2006;208(5):673-685.
 48. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. *Exp Mol Pathol*. 2006;81(2):146-156.
 49. Liu J-W, Shen J-J, Tanzillo-Swarts A, et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. *Oncogene*. 2003;22(10):1475-1485.
 50. Shiozawa Y, Havens AM, Jung Y, et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. *J Cell Biochem*. 2008;105(2):370-380.



blood[®]

2012 120: 1087-1094

doi:10.1182/blood-2012-03-415588 originally published
online June 15, 2012

Clinical and prognostic role of annexin A2 in multiple myeloma

Anja Seckinger, Tobias Meibner, Jérôme Moreaux, Daniela Depeweg, Jens Hillengass, Katja Hose, Thierry Rème, Angela Rösen-Wolff, Anna Jauch, Reinhard Schnettler, Volker Ewerbeck, Hartmut Goldschmidt, Bernard Klein and Dirk Hose

Updated information and services can be found at:

<http://www.bloodjournal.org/content/120/5/1087.full.html>

Articles on similar topics can be found in the following Blood collections

[Lymphoid Neoplasia](#) (2588 articles)

[Multiple Myeloma](#) (369 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>